ALS Continuing Education Module

banner

Course: SS4612
CE Original Date: August 1, 2023
CE Expiration Date: August 1, 2025

To access and begin the National ALS Registry module, please visit the
 National ALS Registry online training module.

Introduction

This training will provide an overview of what is currently known about the Amyotrophic Lateral Sclerosis (ALS) which includes clinical background such as symptoms, diagnosis, treatment, and management. The module also describes the mission and the function of the National ALS Registry as a partner of ALS patients and research community The launching of the ALS Registry module is needed to educate the health care providers so they can inform their patients on the requirements for registering and participating in the program.

PROGRAM DESCRIPTION:

This enduring activity is designed to increase knowledge and change competency of Amyotrophic Lateral Sclerosis and the National ALS Registry practices and strategies.

Objectives:
At the conclusion of the session, the participant should be able to:

  1. Recognize ALS-associated symptoms.
  2. Describe the current epidemiology of ALS among US adult population
  3. Describe how to communicate ALS diagnosis and treatment methods to meet patient’s needs.
  4. Describe the importance of enrolling in the National ALS Registry and Biorepository to the patients for the purpose of surveillance and research.
  5. Describe how to improve collaborative practice across the healthcare team regarding the diagnosis and treatment of patients with amyotrophic lateral sclerosis.

Individuals with disabilities may have difficulty completing the course. If you need assistance, please contact Reshma Punjani at lqx6@cdc.gov and mention you need assistance with the ATSDR Amyotrophic Lateral Sclerosis (ALS) Registry Online Training Module.

This course is provided as part of the National ALS Registry. For information regarding the National ALS Registry, please visit https://www.cdc.gov/als/

Faculty/Credentials 

Paul Mehta, MD, Principal Investigator, Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry

D. Kevin Horton, DrPH, MSPH, Chief, Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry/Registries and Surveillance Section

Wendy Kaye, PhD, Epidemiologist, McKing Consulting Corporation

Reshma Punjani, MPH, Epidemiologist, Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry

Moon Han, PhD, MPH, MS, Senior Service Fellow, Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry

MATERIALS: None

TARGET AUDIENCE: Physicians, Registered Nurses, Epidemiologists, Laboratorians, Physician Assistants, Program Managers

PREREQUISITES:A basic knowledge of medicine or related basics of human health promotion at a professional level is desired for accessing this module. The educational scope of this module would benefit any health care partitioner, especially providers of neurological specialized care, seeking to provide adequate and sufficient training regarding the diagnosis and treatment of amyotrophic lateral sclerosis (ALS).

FORMAT: This activity is Web-based/Web on Demand.

CONTACT INFORMATION: Office of Innovation and Analytics, Registries and Surveillance Section, National ALS Registry

Who is this training for?

Our primary target audience is primary health providers and other health professionals involved in preventing/mitigating exposure to hazardous substances and/or related health promotion activities. The target populations for the ALS are pediatric health care providers, primary health care providers and other health professionals that are interested in environmental health topics; which include: CHES certified health educator; dentists; D.O.s; Epidemiologists; Laboratorians: Licensed practical/vocational nurses; MDs; Medical assistants; Nurse practitioners; Nurse technicians; Other health educators; Physician assistants; Registered nurses; Physicians.

What is this training about?

ALS is a rapidly progressive neuro-degenerative disease. It belongs to a group of disorders known as motor neuron diseases, which are characterized by the gradual degeneration and death of motor neurons. These diseases cause loss of ability to trigger specific muscles, which results in the muscles becoming weak and ultimately leading to paralysis. This educational module provides:

  • A clinical overview on ALS
  • Current clinical practice recommendations for diagnosis, treatment, and management of patients with ALS, including communication strategies
  • Information on the importance of standard diagnostic coding procedures for diagnosis of ALS patients in clinical practice
  • Information on the new National ALS Registry and the importance of ALS patient self-enrollment in the registry

Who developed this continuing education training?

ATSDR’s Division of Toxicology and Human Health Sciences collaboratively developed this online continuing education module.

Acknowledgement of external course contributors and reviewers

ATSDR acknowledges and gives special thanks to Eric Sorenson M.D. and David J. Thurman, MD, MPH, FAAN for their assistance in the development and review of the module. We also acknowledge those who provided formative review and testing of the educational module:

  • Richard D. Franco M.D. (Board certified in Internal Medicine and Neurology)
  • Matthews Gwynn M.D. (Board certified in Internal Medicine and Neurology)
  • Rebecca Heitkam RN, BSN, CCRN
  • Lisa Johnson M.D. (Board certified in Neurology and Sleep Disorders)
  • Barry McCasland M.D. (Board certified in Neurology)
  • Alex Rikhter M.D. (Board certified in Internal Medicine)
  • Keith Sanders M. D. (Board certified in Neurology and Electrodiagnostic Medicine)

Accreditation Statements:

acc

In support of improving patient care, this activity has been planned and implemented by Centers for Disease Control and Prevention and McKing Consulting Corporation. The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

CME: The Centers for Disease Control and Prevention designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention designates this activity for 1.5 nursing contact hours.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.2 CEU’s for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 1.5 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 1.5. Continuing Competency credits available are 1.5. CDC provider number 98614.

For Certified Public Health Professionals (CPH)
The Centers for Disease Control and Prevention is a preapproved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 2.0 CPH recertification credits for this program.

DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies during the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.
CDC, our planners, and content experts wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.

Instructions for Obtaining Continuing Education (CE)

To receive continuing education (CE) for SS4612ALS Registry Continuing Education Module, please visit CDC TRAIN and search for the course in the Course Catalog using [course number]. Follow the steps below by 8/1/2025].

  1. Register for and complete the course.
  2. Pass the post-assessment at 70%.
  3. Complete the evaluation.
  4. Visit Your Learning to access your certificates and transcript.

 FEES: No fees are charged for CDC’s CE activities

Contact Information

For additional information about Environmental Medicine Education Products, please email atsdrdtemce@cdc.gov.